Abstract
Background
Prostate cancer ranks as the eighth leading cause of cancer-related mortality in Thailand,
exhibiting an average annual percent increase in incidence rates of 2.7%. Abiraterone
acetate, an active prodrug of abiraterone, exhibits potent inhibitory activity against
the enzyme CYP17A1, a crucial component in the androgenic biosynthetic cascade. This
study was designed to evaluate the safety and efficacy of generic abiraterone (Abiratred)
in treating metastatic prostate cancer within a real-world, retrospective observational
context.
Materials and Methods
Thirty-five patients diagnosed with metastatic prostate cancer who underwent abiraterone
treatment at Siriraj Hospital in Thailand were enrolled in the study. Data encompassing
demographics, medical history, general examination, vital signs, comorbidities, health
status, and prostate cancer-related characteristics were collected. The primary outcome
measure was the prostate-specific antigen (PSA) response rate (defined as a ≥ 50%
decrease in PSA levels from baseline), and secondary outcomes encompassed assessing
PSA progression-free survival (PFS), disease control rate (DCR), and evaluating safety.
Results
Among the 35 patients, 23 (65.7%) exhibited a PSA response. The median PSA PFS at
6 months was 65.6% (21 out of 35 patients). The DCR was determined to be 71.4% (25
out of 35 patients), with 19 (54.3%) patients experiencing stable disease and 6 (17.1%)
patients showing a partial response. Adverse events were observed in 5 (14.3%) patients,
but there were no deaths related to abiraterone.
Conclusion
This real-world study provides evidence that generic abiraterone (Abiratred) is both
well-tolerated and effective for patients with advanced or metastatic prostate cancer,
making it a promising option in real-world clinical settings.
Keywords abiraterone - androgen deprivation therapy - prostate cancer - prostate-specific antigen
- real-world study
